Heart Disease News and Research

Latest Heart Disease News and Research

Research findings show normal rise and fall in triglycerides

When the circadian rhythm gets thrown off, it could come with an unexpected side effect: high triglycerides. The discovery, based on studies in mice with a "broken clock," helps to explain the normal rise and fall in triglycerides, which happens at about the same time each day, according to researchers who report their findings in the August issue of Cell Metabolism, a Cell Press publication.

4 Aug 2010

Celera decreases second-quarter net loss to $6.1 million

Celera Corporation today reported net revenues of $32.6 million for the second quarter of 2010 that ended June 26, 2010, compared to $41.4 million for the prior year quarter. For the second quarter of 2010, Celera reported a net loss of $6.1 million, or $0.07 per share, compared to a net loss of $31.7 million, or $0.39 per share, for the prior year quarter.

4 Aug 2010

Boston Scientific initiates enrollment in EVOLVE clinical trial of SYNERGY Coronary Stent

Boston Scientific Corporation today announced the start of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of its fourth-generation SYNERGY™ Coronary Stent. The first patient was enrolled by Ian Meredith, M.B.B.S., Ph.D., Professor and Director of MonashHeart, at Monash Medical Centre in Melbourne, Australia.

4 Aug 2010

BCM collaborates with Roche NimbleGen for high throughput exome capture technology

The Baylor College of Medicine Human Genome Sequencing Center has standardized its target enrichment human disease research studies on Roche NimbleGen Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More than 15 different diseases will be investigated by Baylor HGSC, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the goal of better understanding causative mutations and their impact on these diseases.

4 Aug 2010

Arena reports lower net loss of $28.80M for second-quarter 2010

Arena Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010, and recent developments, including the successful Pre-Approval Inspection, or PAI, of the company's Swiss drug product manufacturing facility by the US Food and Drug Administration, or FDA.

4 Aug 2010

CSI launches Diamondback Predator 360 catheter system for treatment of peripheral arterial disease

Cardiovascular Systems, Inc. has launched its second-generation product, the Diamondback Predator 360° PAD System, for the treatment of peripheral arterial disease (PAD). The new device uses the same mechanism of action as the clinically proven Diamondback 360 PAD System with improvements in the crowns and shaft for enhanced clinical performance and shorter procedure times.

4 Aug 2010

POZEN reports $16.2M net income for second-quarter 2010

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2010.

3 Aug 2010

AGA Medical second-quarter 2010 net sales increase 7.6% to $53.8 million

AGA Medical Holdings, Inc., a leading developer of interventional medical devices for the minimally invasive treatment of structural heart defects and vascular abnormalities, today reported financial results for the second quarter ended June 30, 2010.

3 Aug 2010

Kopin second-quarter total sales increase 7.0% to $30.2 million

Kopin Corporation today announced financial results for the second quarter ended June 26, 2010.

3 Aug 2010

Investigators explore legal, ethical permissibility of carrying out request specific to VAD

Patients have the right to refuse or request the withdrawal of any unwanted treatment. In an article published in the online issue of Mayo Clinic Proceedings, investigators explore the legal and ethical permissibility of carrying out such a request specific to a ventricular assist device.

3 Aug 2010

MEDNAX second-quarter revenue increases 9% to $349.1 million

MEDNAX, Inc. today reported earnings per share of $1.04 for the three months ended June 30, 2010, that were driven by contributions resulting from the Company's acquisitions and ongoing operating efficiencies.

3 Aug 2010

Acorda second-quarter net loss decreases to $6.8 million

Acorda Therapeutics, Inc. today announced its financial results for the second quarter of 2010.

3 Aug 2010

Pairing adolescents with college student mentors keeps kids healthy, fit

A program pairing healthy young adults with urban middle school students helped the adolescents adopt healthy habits, active lifestyles and a healthy weight, according to a new study from the University of Maryland School of Medicine. The study, published August 2 in the journal Pediatrics, found that linking African American, inner city adolescents in Baltimore with one-on-one mentorship from college students prevented the schoolchildren from becoming overweight for at least two years after the mentorship experience. Researchers found the adolescents ate fewer snacks and desserts, and engaged in active play more often. The rate of overweight/obesity in the group declined five percent.

3 Aug 2010

Toxic protein in bee venom improves liposome encapsulated drug effectiveness

The next time you are stung by a bee, here's some consolation: a toxic protein in bee venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs or dyes, such as those already used to treat or diagnose cancer. This research, described in the August 2010 print issue of the FASEB Journal, shows how modified melittin may revolutionize treatments for cancer and perhaps other conditions, such as arthritis, cardiovascular disease, and serious infections.

3 Aug 2010

Menstrual cycle affects body's response to tracheal intubation: Research

In women undergoing surgery, the heart rate and blood pressure response to ventilation tube placement varies at different times of the menstrual cycle, according to a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

3 Aug 2010

Diffusion Pharmaceuticals receives patent for drug formulation

Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled "Bipolar Trans Carotenoid Salts and Their Uses." This patent includes drug formulation and use claims relating to Diffusion's entire family of first-in-class new chemical entities. Diffusion Pharmaceuticals is commercializing this family of first-in-class drug candidates to treat serious or life-threatening medical conditions characterized by hypoxia or oxygen deprivation at the cellular level.

3 Aug 2010

Study finds low carbohydrate diet may help improve cardiovascular risk factors

The effectiveness of a low-carbohydrate diet versus a low-fat diet for weight loss have been frequently debated. According to a new study published in Annals of Internal Medicine, both diets produce identical weight loss when coupled with comprehensive behavior treatment, but a low-carbohydrate diet may help improve cardiovascular risk factors.

3 Aug 2010

Americans halved their risk of dying from CHD over past 20 years: Study

By smoking less, watching their cholesterol and lowering their high blood pressure, Americans halved their risk of dying from coronary heart disease over the past 20 years, a new study shows.

3 Aug 2010

Emerging Healthcare Solutions executes Term Sheet with Stand-By Systems

Emerging Healthcare Solutions, Inc. disclosed today that the Company has executed a Term Sheet with Stand-By Systems. The Term Sheet represents successful negotiations between the two companies just ahead of finalizing a Definitive Agreement. Stand-By Systems (SBS) owns the FDA approved SBS 1615 catalytic oxygen generator and associated systems. This cutting edge generator provides medical grade USP oxygen at the push of a button from self-contained inert dry compounds.

3 Aug 2010

miRagen Therapeutics develop MicroRNA based therapeutics for cardiovascular and muscle disease

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.

3 Aug 2010